Between 19 August 2022 and 26 September 2022, we sought submissions from the public on the interim decisions made for the substances discussed at the March 2022 meeting of the Advisory Committees on Medicines and Chemicals Scheduling. Respondents were given the choice to indicate their support or opposition to the interim decisions using survey buttons, with or without a written response.
Azelastine and fluticasone propionate: A total of 5 responses were received, 2 were in support, 2 in partial support and 1 opposing the interim decision. Of these responses, 1 submissions in support, 2 submissions in partial support, and 1 submission opposing the interim decision contained a written component.
Cannabis and tetrahydrocannabinols: A total of 5 responses were received, 4 in support and 1 opposing the interim decision. Of these responses, 3 submissions in support and 1 submission opposing the interim decision contained a written component.
Lead: A total of 6 responses were received for lead, 1 in support, 1 in partial support and 4 opposing the interim decision. All 6 responses contained written components.
Meloxicam: A total of 90 responses were received for meloxicam, 13 in support, 2 in partial support and 75 opposing the interim decision. Of these responses, a total of 81 submissions contained a written component, 12 in support, 2 in partial support and 67 opposing the interim decision. We note that several of these written submissions were campaign wording.
Lidocaine: A total of 74 responses were received for lidocaine, 7 in support and 67 opposing the interim decision. Of these responses, 6 submissions in support and 60 submissions opposing the interim decision contained a written component.
Flumioxazin: A total of 2 responses were received for flumioxazin, 1 in partial support and 1 opposing the interim decision. Both submissions contained a written component.
The Delegate of the Secretary of the Department of Health and Aged Care that is responsible for Medicines and Chemicals Scheduling considered all submissions prior to making their final decisions. The final decisions on the proposed amendments to the Poisons Standard were published on 18 November 2022.
View submitted responses where consent has been given to publish the response.
Scheduling amendments referred to expert advisory committee
This consultation is for interim decisions made in relation to applications and delegate initiated proposals to amend the Poisons Standard, following advice sought at the 15-16th March 2022 meetings of the Advisory Committee on Medicines Scheduling (ACMS) and the Advisory Committee on Chemicals Scheduling (ACCS).
The closing date for this consultation is close of business 16 September 2022. All submissions received by the deadline will be considered by the delegate before they make a final decision.
The interim decisions under consultation are detailed in the public notice of interim decisions of March 2022.
Substances for which public comment is sought
All public submissions will be published on the TGA website at Public submissions on scheduling matters, unless marked confidential or indicated otherwise in the submission information (see Privacy and your Personal information).
Public submissions are an important part of the process for amending the Poison Standard, and are published on the TGA website using the consultation hub. Submissions by the public may not reflect the views of the Department of Health or TGA. Published submissions should not be taken as being endorsed by the Department or TGA.
Following consideration of public submissions received before the closing date and advice from the expert advisory committees, decisions on the proposed amendments are anticipated to be published as final decisions on the TGA website: Scheduling delegate's final decisions in October 2022.
Share
Share on Twitter Share on Facebook